Targeting USP47 enhances the efficacy of KRAS inhibitor in KRASG12C mutated non-small cell lung cancer by controlling deubiquitination of c-Myc

FDA-approved KRASG12C inhibitors, like Sotorasib, target G12C-mutated KRAS in NSCLC. However, issues with insensitivity and drug resistance have emerged, requiring the development of new combination therapies to overcome these limitations. USP47 has been identified as a regulator of cancer-related s...

詳細記述

書誌詳細

主要な著者:	Hyungkyung Shin, SuA Hwang, Jeong Hyun Jeong, Sang Chul Shin, Yeonji Oh, Jinhyeok Kim, Inah Hwang, Eunice EunKyeong Kim, Hyunah Choo, Eun Joo Song
フォーマット:	Artigo
言語:	Inglês
出版事項:	Elsevier 2025-05-01
シリーズ:	Pharmacological Research
主題:	USP47 NSCLC C-Myc KRAS Sotorasib
オンライン･アクセス:	http://www.sciencedirect.com/science/article/pii/S1043661825001471
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!